<DOC>
	<DOCNO>NCT00880412</DOCNO>
	<brief_summary>The objective 3-month study ass safety efficacy EHT 0202 addition acetylcholinesterase inhibitor patient suffer Alzheimer 's Disease .</brief_summary>
	<brief_title>A Study Determine Clinical Safety/Tolerability Exploratory Efficacy EHT 0202 Adjunctive Therapy Acetylcholinesterase Inhibitor Mild Moderate Alzheimer 's Disease</brief_title>
	<detailed_description>The aim pilot study assess safety tolerability profile 2 dos EHT 0202 ( 40 mg 80 mg b.i.d ) versus placebo addition treatment acetylcholinesterase inhibitor exploratory efficacy cognition , behavior , activity daily live , caregiver 's burden patient 's global assessment , 3-month treatment period .</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Etazolate</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<criteria>Ambulatory male female patient , age 6090 year old include screening , live home . Patient clinical diagnosis probable AD accord National Institute Neurological Communicative Disorders Stroke/Alzheimer 's Disease Related Disorders Association ( NINCDSADRDA ) criterion . Mild moderate AD MMSE total score ≥ 12 ≤ 24 screening . Written inform consent obtain patient , appropriate , legal representative accord local law regulation . The caregiver also sign specific informed consent form regard his/her participation study . Patient treat AD treatment one AChEI ( donepezil , galantamine , rivastigmine ) , accord recommend posology mention summary product characteristic , least 3 month stable dose least 2 month prior screen . The dose kept unchanged throughout study duration . Patient cerebral CTscan cerebral MRI compatible AD diagnosis , brain lesion may relate another diagnosis could responsible current patient 's condition ( ex , limited , nonAD dementia , brain injury , brain tumour , stroke , normal pressure hydrocephalus , … ) . A cerebral CTscan cerebral MRI perform result available prior patient 's randomization result brain imagery perform settle AD diagnosis available patient 's file . Brain imaging also perform consider necessary investigator , case emerge neurological symptom case worsen exist neurological symptom . Neurological exam without particularity without specific focal sign likely related condition AD . No contraindication AChEI treatment absence significant adverse event consider related AChEI treatment screen randomisation . Patient patient 's caregiver able comply study procedure , notably regard drug intake end meal supervise caregiver another competent person . Diagnosis vascular dementia accord NINDSAIREN criterion , nonAD dementia , CNS pathology ( include limit brain injury , brain tumour , stroke , normal pressure hydrocephalus , Parkinson 's disease , epilepsy , multiple sclerosis , … ) may responsible dementia . Clinically significant pathology and/or uncontrolled condition , include limited cancer , infectious ( like AIDS ) , gastrointestinal , hepatic , renal , respiratory , endocrine ( like diabetes mellitus , thyroiditis ) pathology . History current clinically significant psychiatric pathology ( include limit psychotic disorder , bipolar disorder , personality disorder ) may interfere study assessment . Current major depressive disorder , either treat , associate clinically significant symptom . Low blood level vitamin B12 , TSH level normal range screening . Current forbidden medication intake intake within 2 week prior screen . Recent history ( within past year prior inclusion ) current cardiovascular pathology and/or symptom consider clinically significant , include limited angina pectoris , uncontrolled arrhythmia , significant ECG abnormality . Lifetime history heart failure , myocardial infarction , severe and/or uncontrolled angina pectoris , and/or ventricular arrhythmia disqualifies patient . History presence clinically condition may interfere product metabolism study assessment . Systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 90 mmHg screen and/or randomisation . QTc interval ( Bazett 's correction ) ≥ 430 msec male ≥ 450 msec female screening . Laboratory value ( biochemistry , haematology , urinalysis ) consider clinically significant and/or may interfere study assessment , accord investigator . ALAT , ASAT , ALP &gt; 2.5 time upper normal limit ( UNL ) , total bilirubin &gt; 1.5 UNL history significant liver pathology include hepatitis cause drug , HBV , HCV . BUN , creatinin &gt; 1.5 UNL . Current recent history drug alcohol abuse dependence . Patient register `` Sécurité Sociale '' . Participation another study within 1 month prior screen whole duration study .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>safety</keyword>
	<keyword>efficacy</keyword>
	<keyword>Alzheimer 's disease</keyword>
	<keyword>treatment</keyword>
	<keyword>phase II</keyword>
	<keyword>study</keyword>
	<keyword>cholinesterase inhibitor</keyword>
</DOC>